Hepatotoxicity related to intracavernous pharmacotherapy with papaverine
- 1 November 1998
- Vol. 52 (5), 844-847
- https://doi.org/10.1016/s0090-4295(98)00290-8
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Pharmacokinetics of Vasoactive Substances Administered into the Human Corpus CavernosumJournal of Urology, 1994
- Factors predicting efficacy of phentolamine-papaverine intracorporeal injection for treatment of erectile dysfunction in diabetic maleUrology, 1992
- Comparative Value of Prostaglandin E1 and Papaverine in Treatment of Erectile Failure: Double-Blind Crossover Study among Egyptian PatientsJournal of Urology, 1992
- Twelve-month comparison of two treatments for erectile dysfunction: Self-injection versus external vacuum devicesUrology, 1992
- The use of prostaglandin E1 for diagnosis and treatment of erectile dysfunctionWorld Journal of Urology, 1990
- Side Effects of Self-Administration of Intracavernous Papaverine and Phentolamine for the Treatment of ImpotenceJournal of Urology, 1989
- Intracavernous Injection of Prostaglandin E1 in Impotent MenJournal of Urology, 1988
- Cavernosal Alpha-Blockade: A New Technique for Investigating and Treating Erectile ImpotenceThe British Journal of Psychiatry, 1983
- Papaverine - Hepatotoxic or Not?*Journal of the American Geriatrics Society, 1973
- Hepatotoxicity Due to Treatment with PapaverineNew England Journal of Medicine, 1969